Twenty-four hours after the news broke that he tested positive for steroids, former UFC middleweight champion Anderson Silva broke his silence.
Silva tested positive for Drostanolone and Androstane in an out-of-competition drug test administered on Jan. 9, three weeks prior to his UFC 183 headlining bout with Nick Diaz. Silva won the bout via unanimous decision.
The results of the test weren’t reported to the Nevada Athletic Commission until Tuesday, Feb. 3, but they quickly became public.
The UFC immediately issued a statement about the matter, but Silva had remained quiet until his management sent the following statement denying any wrongdoing to MMAWeekly.com on Wednesday.
“I’ve been competing in this sport for a very long time. This is my nineteenth fight in the UFC. I have been thoroughly tested many times and have never had a positive drug test,” said Silva.
“I have not taken any performance enhancing drugs. My stance on drugs is, and will always be, the same. I’m an advocate for a clean sport,” he continued.
“I’m consulting with my advisors right now to explore all of my options and intend to fight this allegation and clear my name. I will not make any further comments until my team advises me to do so.”
Silva has the option of requesting the B sample from his drug test be processed, which could put the initial A sample result in question or it could verify it. Nevada Athletic Commission executive director Bob Bennett told MMWeekly.com on Wednesday afternoon that Silva’s camp had not yet made such a request.
> SEE ALSO: Anderson Silva's Failed Drug Test Report
Currently, Silva is under a temporary suspension, at least until he has a hearing before the Nevada Athletic Commission.
He could address the commission at its Feb. 17 meeting, but does not have to address the commission that soon. He has twenty days from the written notice of his positive drug test in which to respond. So he is within his rights to respond after the Feb. 17 date.
If that happens, the soonest Silva would go before the commission for a full hearing would be at the commission’s regular meeting in March, which has yet to be scheduled.